Keros Historical Cash Flow
| KROS Stock | USD 10.77 0.22 2.00% |
Analysis of Keros Therapeutics cash flow over time is an excellent tool to project Keros Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 180 M or Other Cashflows From Financing Activities of 9.2 M as it is a great indicator of Keros Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Keros Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Keros Therapeutics is a good buy for the upcoming year.
Keros |
About Keros Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Keros balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Keros's non-liquid assets can be easily converted into cash.
Keros Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Keros Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Keros Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.At this time, Keros Therapeutics' Cash And Cash Equivalents Changes is comparatively stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Other Non Cash Items | 953K | 1.6M | 1.8M | 1.5M | Depreciation | 674K | 815K | 1.2M | 1.3M |
Keros Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Keros Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Keros Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Sale Purchase Of Stock | 14K | 299.0M | 28.6M | 120.3M | 138.4M | 101.1M | |
| Investments | (294K) | (1.0M) | (1.2M) | (2.5M) | (1.9M) | (1.8M) | |
| Change In Cash | 258.9M | (34.6M) | 49.0M | 52.0M | 229.0M | 240.5M | |
| Stock Based Compensation | 4.1M | 11.7M | 18.7M | 28.8M | 34.9M | 36.6M | |
| Free Cash Flow | (37.2M) | (63.2M) | (71.3M) | (127.0M) | (162.8M) | (154.7M) | |
| Change In Working Capital | 2.3M | (16.1M) | 14.3M | (2.7M) | (11.4M) | (10.9M) | |
| Begin Period Cash Flow | 7.1M | 266.0M | 231.4M | 280.4M | 332.4M | 180.0M | |
| Total Cashflows From Investing Activities | (271K) | (294K) | (1.0M) | (1.2M) | (1.1M) | (1.1M) | |
| Other Cashflows From Financing Activities | 52.8M | 379K | 731K | 3.1M | 11.7M | 9.2M | |
| Depreciation | 278K | 378K | 674K | 815K | 1.2M | 1.3M | |
| Other Non Cash Items | 1.8M | 520K | 953K | 1.6M | 1.8M | 1.5M | |
| Capital Expenditures | 294K | 1.0M | 1.2M | 2.5M | 1.9M | 1.2M | |
| Total Cash From Operating Activities | (36.9M) | (62.1M) | (70.1M) | (124.5M) | (160.9M) | (152.8M) | |
| Change To Account Receivables | 922K | (18M) | 18M | (143K) | (2.6M) | (2.5M) | |
| Change To Operating Activities | 2.0M | 2.2M | 445K | (3.3M) | (3.0M) | (2.8M) | |
| Issuance Of Capital Stock | 299.2M | 28.2M | 119.6M | 175.8M | 380.1M | 399.1M | |
| Net Income | (45.4M) | (58.7M) | (104.7M) | (153.0M) | (187.4M) | (178.0M) | |
| Total Cash From Financing Activities | 296.0M | 28.6M | 120.3M | 179.0M | 391.8M | 411.4M | |
| End Period Cash Flow | 266.0M | 231.4M | 280.4M | 332.4M | 561.4M | 589.4M | |
| Change To Netincome | 2.9M | 5.9M | 11.8M | 18.7M | 21.5M | 22.6M | |
| Change To Liabilities | (8.7M) | 61K | 4.1M | 4.9M | 5.7M | 5.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.